Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

EQS-News: PAION AG’S PARTNER TTY BIOPHARM RECEIVES MARKET APPROVAL FOR REMIMAZOLAM IN PROCEDURAL SEDATION IN TAIWAN: https://upload.wikimedia.org/wikipedia/de/thumb/4/45/Paion-logo.svg/640px-Paion-logo.svg.png
EQS-News: PAION AG’S PARTNER TTY BIOPHARM RECEIVES MARKET APPROVAL FOR REMIMAZOLAM IN PROCEDURAL SEDATION IN TAIWAN
EQS-News: PAION AG’S PARTNER TTY BIOPHARM RECEIVES MARKET APPROVAL FOR REMIMAZOLAM IN PROCEDURAL SEDATION IN TAIWAN
Dexcom Invites the Diabetes Community to #seediabetes This November and Share Their Diabetes Story With Custom Continuous Glucose Monitor (CGM) Patches: https://mms.businesswire.com/media/20221114005152/en/1634599/5/WDD_Patches.jpg
Dexcom Invites the Diabetes Community to #seediabetes This November and Share Their Diabetes Story With Custom Continuous Glucose Monitor (CGM) Patches


DexCom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring, its global partners and Dexcom Warriors will once again help the world #SeeDiabetes and empower members of

EQS-News: Biotest AG: Biotest reports sales of Euro 361 million in the first nine months of 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24092/375px-Biotest_logo.svg.png
EQS-News: Biotest AG: Biotest reports sales of Euro 361 million in the first nine months of 2022
EQS-News: Biotest AG: Biotest reports sales of Euro 361 million in the first nine months of 2022
EQS-News: Biotest AG: Biotest receives approval for new intravenous immunoglobulin Yimmugo® (IgG Next Generation): http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24092/375px-Biotest_logo.svg.png
EQS-News: Biotest AG: Biotest receives approval for new intravenous immunoglobulin Yimmugo® (IgG Next Generation)
EQS-News: Biotest AG: Biotest receives approval for new intravenous immunoglobulin Yimmugo® (IgG Next Generation)
EQS-News: HAEMATO AG: publishes figures for the 3rd quarter 2022http://www.haemato-ag.de/: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/13910/haematoLogo.png
EQS-News: HAEMATO AG: publishes figures for the 3rd quarter 2022
EQS-News: HAEMATO AG: publishes figures for the 3rd quarter 2022
EQS-News: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
EQS-News: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
EQS-Adhoc: Ad hoc: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-Adhoc: Ad hoc: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
EQS-Adhoc: Ad hoc: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
EQS-Adhoc: GN Store Nord A/S: GN announces appointment of new CEO in GN Audio: https://mms.businesswire.com/media/20220816005068/en/1543852/5/GN_Logo_RGB_300ppi.jpg
EQS-Adhoc: GN Store Nord A/S: GN announces appointment of new CEO in GN Audio
EQS-Adhoc: GN Store Nord A/S: GN announces appointment of new CEO in GN Audio
EQS-News: Invitation to MorphoSys’ Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: Invitation to MorphoSys’ Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022
EQS-News: Invitation to MorphoSys’ Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022
U.S. News and World Report names Humana 2023 Best Overall Medicare Advantage Plan Company: https://mms.businesswire.com/media/20221110005219/en/1632000/5/US_News_and_World_Report_badges.jpg
U.S. News and World Report names Humana 2023 Best Overall Medicare Advantage Plan Company


Humana recently received recognition as U.S. News & World Report’s Best Insurance Company for Medicare Advantage in three categories for 2023.


This press release features multimedia. View the full

EQS-News: RHÖN-KLINIKUM AG closes first nine months of 2022 with revenue surplus : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23735/Rhoen-klinikum.svg.png
EQS-News: RHÖN-KLINIKUM AG closes first nine months of 2022 with revenue surplus
EQS-News: RHÖN-KLINIKUM AG closes first nine months of 2022 with revenue surplus
EQS-News: Evotec SE reports results for the first nine months 2022 and provides corporate update: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec SE reports results for the first nine months 2022 and provides corporate update
EQS-News: Evotec SE reports results for the first nine months 2022 and provides corporate update
EQS-News: Biotest AG: Biotest reports sales of Euro 361 million in the first nine months of 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24092/375px-Biotest_logo.svg.png
EQS-News: Biotest AG: Biotest reports sales of Euro 361 million in the first nine months of 2022
EQS-News: Biotest AG: Biotest reports sales of Euro 361 million in the first nine months of 2022
EQS-News: MorphoSys to Share New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys to Share New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting
EQS-News: MorphoSys to Share New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting
EQS-News: Evotec SE to announce results for the first nine months 2022 on 09 November 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec SE to announce results for the first nine months 2022 on 09 November 2022
EQS-News: Evotec SE to announce results for the first nine months 2022 on 09 November 2022
EQS-News: Evotec completes acquisition of Central Glass Germany: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec completes acquisition of Central Glass Germany
EQS-News: Evotec completes acquisition of Central Glass Germany
AEVIS VICTORIA SA – AEVS.SW – Nine-month revenues up 35.5% to CHF 831.0 millionhttp://www.aevis.com: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/12720/aevis-logo.png
AEVIS VICTORIA SA – AEVS.SW – Nine-month revenues up 35.5% to CHF 831.0 million
AEVIS VICTORIA SA – AEVS.SW – Nine-month revenues up 35.5% to CHF 831.0 million
EQS-News: STRATEC REPORTS RESULTS FOR FIRST NINE MONTHS OF 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24071/375px-Stratec-Biomedical-Logo.svg.png
EQS-News: STRATEC REPORTS RESULTS FOR FIRST NINE MONTHS OF 2022
EQS-News: STRATEC REPORTS RESULTS FOR FIRST NINE MONTHS OF 2022
EQS-Adhoc: GN Store Nord A/S: GN Store Nord’s Audio division revises financial guidance for 2022: https://mms.businesswire.com/media/20220816005068/en/1543852/5/GN_Logo_RGB_300ppi.jpg
EQS-Adhoc: GN Store Nord A/S: GN Store Nord’s Audio division revises financial guidance for 2022
EQS-Adhoc: GN Store Nord A/S: GN Store Nord’s Audio division revises financial guidance for 2022
EQS-News: Evotec presents paradigm shift in biologics at Capital Markets Day: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec presents paradigm shift in biologics at Capital Markets Day
EQS-News: Evotec presents paradigm shift in biologics at Capital Markets Day
Dexcom Partners With Warriors and Nonprofits to Artfully Advocate for Access to Diabetes Care: https://mms.businesswire.com/media/20221101005121/en/1618893/5/NDAM_News_Release_Photo.jpg
Dexcom Partners With Warriors and Nonprofits to Artfully Advocate for Access to Diabetes Care


DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes will come together with members of the diabetes community during National Diabetes

CORRECTING and REPLACING Acadia Healthcare Reports Third Quarter 2022 Results
CORRECTING and REPLACING Acadia Healthcare Reports Third Quarter 2022 Results


There was an inadvertent error on the supplementary table titled “Reconciliation of Net Income Attributable to Acadia Healthcare Company, Inc. to Adjusted Income Attributable to Acadia Healthcare

EQS-Adhoc: Challenging macroeconomic environment impact Fresenius Medical Care and Fresenius Group earnings in FY/22; Fresenius SE & Co. KGaA Group guidance revised: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24693/Fresenius.svg.png
EQS-Adhoc: Challenging macroeconomic environment impact Fresenius Medical Care and Fresenius Group earnings in FY/22; Fresenius SE & Co. KGaA Group guidance revised
EQS-Adhoc: Challenging macroeconomic environment impact Fresenius Medical Care and Fresenius Group earnings in FY/22; Fresenius SE & Co. KGaA Group guidance revised
EQS-News: Fresenius Medical Care AG & Co. KGaA revises financial outlook for full year 2022 : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23608/Fresenius_Medical_Care_20xx_logo.svg.png
EQS-News: Fresenius Medical Care AG & Co. KGaA revises financial outlook for full year 2022
EQS-News: Fresenius Medical Care AG & Co. KGaA revises financial outlook for full year 2022
EQS-Adhoc: Fresenius Medical Care AG & Co. KGaA extends net income target range for financial year 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23608/Fresenius_Medical_Care_20xx_logo.svg.png
EQS-Adhoc: Fresenius Medical Care AG & Co. KGaA extends net income target range for financial year 2022
EQS-Adhoc: Fresenius Medical Care AG & Co. KGaA extends net income target range for financial year 2022